tetano
Editor, Senior Moderator
Influenza Other Respir Viruses. 2016 Jul 28. doi: 10.1111/irv.12418. [Epub ahead of print]
[h=1]Assessment of antigenic difference of equine influenza virus strains by challenge study in horses.[/h] Yamanaka T[SUP]1[/SUP], Nemoto M[SUP]1,[/SUP][SUP]2[/SUP], Bannai H[SUP]1[/SUP], Tsujimura K[SUP]1[/SUP], Kondo T[SUP]1[/SUP], Matsumura T[SUP]1[/SUP], Gildea S[SUP]2[/SUP], Cullinane A[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] We previously reported that horse antiserum against the Japanese equine influenza vaccine virus, A/equine/La Plata/1993 (LP93) exhibited reduced cross-neutralization against some Florida sublineage Clade (Fc) 2 viruses, e.g. A/equine/Carlow/2011 (CL11). As a result Japanese vaccine manufacturers will replace LP93 with A/equine/Yokohama/aq13/2010 (Y10, Fc2). To assess the benefit of updating the vaccine, five horses vaccinated with inactivated Y10 vaccine and five vaccinated with inactivated LP93 were challenged by exposure to a nebulized aerosol of CL11. The durations of pyrexia (≥38.5?C) and other adverse clinical symptoms experienced by the Y10 group were significantly shorter than those of the LP93 group. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] H3N8; challenge study; equine influenza; inactivated whole vaccine
PMID: 27465864 DOI: 10.1111/irv.12418
[PubMed - as supplied by publisher] Free full text
[h=1]Assessment of antigenic difference of equine influenza virus strains by challenge study in horses.[/h] Yamanaka T[SUP]1[/SUP], Nemoto M[SUP]1,[/SUP][SUP]2[/SUP], Bannai H[SUP]1[/SUP], Tsujimura K[SUP]1[/SUP], Kondo T[SUP]1[/SUP], Matsumura T[SUP]1[/SUP], Gildea S[SUP]2[/SUP], Cullinane A[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] We previously reported that horse antiserum against the Japanese equine influenza vaccine virus, A/equine/La Plata/1993 (LP93) exhibited reduced cross-neutralization against some Florida sublineage Clade (Fc) 2 viruses, e.g. A/equine/Carlow/2011 (CL11). As a result Japanese vaccine manufacturers will replace LP93 with A/equine/Yokohama/aq13/2010 (Y10, Fc2). To assess the benefit of updating the vaccine, five horses vaccinated with inactivated Y10 vaccine and five vaccinated with inactivated LP93 were challenged by exposure to a nebulized aerosol of CL11. The durations of pyrexia (≥38.5?C) and other adverse clinical symptoms experienced by the Y10 group were significantly shorter than those of the LP93 group. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] H3N8; challenge study; equine influenza; inactivated whole vaccine
PMID: 27465864 DOI: 10.1111/irv.12418
[PubMed - as supplied by publisher] Free full text